Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Keli-med is a topical scar treatment cream developed and marketed by Permamed. It is formulated with a synergistic combination of active ingredients designed to promote optimal scar healing, prevent hypertrophic scar and keloid formation, and protect healing tissue from ultraviolet radiation. The active components include onion extract (Allii cepae extractum), which inhibits fibroblast function and exerts fibrinolytic effects; hyoscyamus oil macerate (henbane oil), traditionally used to soothe and treat scars; allantoin, which promotes tissue hydration and regeneration; and heparin sodium, which provides antithrombotic, anti-inflammatory, and analgesic properties while facilitating tissue resorption. Additionally, Keli-med contains the UV-A filter avobenzone and the UV-B filter enzacamene to protect melanin-deficient scar tissue from sun damage. It is indicated for the prophylaxis and treatment of hypertrophic scars and keloids resulting from surgeries, skin transplants, burns, and other injuries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Keli-med.